BLOOMFIELD, Conn., April 19, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at the BofA Securities 2023 Health Care Conference on May 10, 2023 in Las Vegas, NV.
The Cigna Group's presentation is expected to begin at approximately 12:20 p.m. ET. A live webcast of the presentation will be available at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website
To listen to this presentation live on the Internet, visit https://investors.thecignagroup.com/events-and-presentations/default.aspx at least 15 minutes prior to the presentation to download and install any necessary audio software.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 190 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
Ralph.Giacobbe@TheCignaGroup.com
Media Contact
Justine Sessions
1 (860) 810-6523
Justine.Sessions@cigna.com
| Last Trade: | US$308.86 |
| Daily Change: | 5.51 1.82 |
| Daily Volume: | 2,595,086 |
| Market Cap: | US$85.910B |
January 30, 2025 October 31, 2024 September 12, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
